VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwAL 2018 | Liposomal chemotherapy CPX-351: safety profile

CPX-351, a combination of cytarabine (ara-C) and daunorubicin within a liposomal delivery system, was approved in August 2017 for two types of secondary acute myeloid leukemia (AML). Speaking from the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, Jeffrey Lancet, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the safety profile of this exciting drug.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter